Daily Endocrinology Research Analysis
A phase 3 randomized trial shows semaglutide 2.4 mg weekly significantly improves histology in MASH with stage F2–F3 fibrosis at 72 weeks. A network meta-analysis suggests early combination therapy outperforms monotherapy for initial pharmacologic management of type 2 diabetes. A large UK cohort of conservatively managed non-functioning pituitary macroadenomas provides data to safely de-intensify imaging and endocrine testing in selected patients.
Summary
A phase 3 randomized trial shows semaglutide 2.4 mg weekly significantly improves histology in MASH with stage F2–F3 fibrosis at 72 weeks. A network meta-analysis suggests early combination therapy outperforms monotherapy for initial pharmacologic management of type 2 diabetes. A large UK cohort of conservatively managed non-functioning pituitary macroadenomas provides data to safely de-intensify imaging and endocrine testing in selected patients.
Research Themes
- GLP-1 receptor agonists for steatohepatitis
- Early combination therapy strategies in type 2 diabetes
- Risk-adapted surveillance of non-functioning pituitary macroadenomas
Selected Articles
1. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
In a 72-week interim analysis of a phase 3 RCT in biopsy-proven MASH with stage F2–F3 fibrosis, semaglutide 2.4 mg weekly significantly increased steatohepatitis resolution and fibrosis improvement versus placebo and produced substantial weight loss. Gastrointestinal adverse events were more frequent with semaglutide.
Impact: This is the first large phase 3 trial demonstrating histologic benefit of a GLP-1 receptor agonist in MASH, a condition with no widely approved pharmacotherapy. It establishes semaglutide as a strong candidate to change MASH management.
Clinical Implications: For patients with MASH and fibrosis F2–F3, semaglutide 2.4 mg weekly can be considered to achieve NASH resolution and potential fibrosis benefit alongside weight loss, while monitoring gastrointestinal tolerability. Long-term outcomes (240 weeks) and regulatory approvals will guide adoption.
Key Findings
- Steatohepatitis resolution without fibrosis worsening: 62.9% with semaglutide vs 34.3% with placebo (difference 28.7 pp; P<0.001).
- Fibrosis improvement without steatohepatitis worsening: 36.8% vs 22.4% (difference 14.4 pp; P<0.001).
- Combined resolution and fibrosis improvement: 32.7% vs 16.1% (P<0.001).
- Mean body weight change: −10.5% with semaglutide vs −2.0% with placebo.
- Gastrointestinal adverse events were more frequent with semaglutide.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled phase 3 design.
- Biopsy-defined MASH with prespecified co-primary histologic endpoints and multiplicity adjustment for key secondary outcomes.
Limitations
- Interim analysis at 72 weeks; long-term clinical outcomes (e.g., decompensation, mortality) are pending.
- Fibrosis improvement effect size was modest; GI adverse events may limit tolerability in some patients.
Future Directions: Await 240-week outcomes for clinical endpoints and durability; evaluate combination regimens (e.g., GLP-1RA plus antifibrotics) and real-world effectiveness across fibrosis stages.
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
2. Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.
This PRISMA-compliant network meta-analysis of RCTs in early T2D found that initial combination therapy outperforms monotherapy for HbA1c reduction at 6 months, with metformin plus GLP-1RA or DPP-4 inhibitor ranking highest. GLP-1RA and SGLT2 inhibitors promoted weight loss; hypoglycemia risk was increased with sulfonylureas.
Impact: It synthesizes randomized evidence to support early dual therapy, informing initial treatment algorithms beyond traditional stepwise escalation.
Clinical Implications: For newly diagnosed or early T2D, consider initiating combination therapy—particularly metformin plus a GLP-1RA or DPP-4 inhibitor—to achieve greater early HbA1c reduction and leverage weight benefits (GLP-1RA/SGLT2), while individualizing to hypoglycemia risk and patient preferences.
Key Findings
- All combination therapies were superior to monotherapy for 6‑month HbA1c reduction.
- Top-ranked regimens: metformin+GLP‑1RA (WMD −1.50%) and metformin+DPP‑4 inhibitor (WMD −1.46%).
- GLP‑1RA and SGLT2 inhibitors produced weight loss; sulfonylureas increased hypoglycemia risk.
- No overall increase in adverse events across regimens aside from sulfonylurea-related hypoglycemia.
Methodological Strengths
- PRISMA-compliant systematic review with network meta-analysis of randomized trials.
- Compared multiple drug classes and combinations across efficacy and safety outcomes.
Limitations
- Short-term (6-month) outcomes; durability and long-term safety not addressed.
- Heterogeneity across included trials and potential transitivity assumptions inherent to network meta-analysis.
Future Directions: Head-to-head pragmatic trials of early combination strategies with potent GLP-1RAs and SGLT2 inhibitors, longer-term cardiovascular/renal outcomes, and cost-effectiveness analyses.
BACKGRUOUND: Type 2 diabetes mellitus (T2DM) requires stringent glycemic control from an early stage to prevent complications. The most effective treatment regimen for early T2DM remains unclear. The study aimed to compare the efficacy and safety of monotherapies and combination therapies for early T2DM. METHODS: A systematic review and network meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Randomized controlled trials focused on glycemic control, body weight, and adverse events were included. The primary outcomes were changes in glycosylated hemoglobin (HbA1c) and odds of achieving the target HbA1c after 6 months. RESULTS: All combination therapies were more effective than monotherapy. Metformin+glucagon-like peptide-1 receptor agonists (GLP-1RA) (weighted mean difference [WMD] -1.50%; 95% confidence interval [CI] -2.04 to -0.96) and metformin+dipeptidyl peptidase-4 inhibitors (WMD -1.46%; 95% CI, -1.96 to -0.95) were the most effective for change in HbA1c. GLP-1RA and sodium- glucose cotransporter-2 inhibitors led to weight reduction. Apart from the increased risk of hypoglycemia with sulfonylureas, no significant differences in adverse events were observed across regimens. CONCLUSION: Early combination therapy effectively improved glycemic control in patients with early T2DM without significantly increasing adverse risks. Future studies should explore new combinations, including potent GLP-1RA.
3. Conservatively managed non-functioning pituitary macroadenomas-cohort study from the UK Non-functioning Pituitary Adenoma Consortium.
In 949 conservatively managed macroNFPAs, tumor enlargement occurred at 9.8 per 100 patient-years; five-year cumulative growth probability was 43.6%. For lesions not contacting the optic chiasm, short-term enlargement rarely affected visual fields, and new hypopituitarism was uncommon in stable tumors, supporting less frequent imaging and selective endocrine testing.
Impact: Provides the largest multicenter dataset to date guiding surveillance intervals and endocrine monitoring for macroNFPAs, enabling risk-adapted, less burdensome follow-up.
Clinical Implications: For macroNFPAs not contacting the optic chiasm, the first follow-up MRI can be delayed to 12 months and imaging performed less frequently thereafter; routine periodic pituitary hormone testing may be unnecessary in stable lesions, reserving closer follow-up for tumors abutting the chiasm or enlarging.
Key Findings
- Tumor enlargement incidence: 9.8 per 100 patient‑years (95% CI 8.8–10.8); 5‑year cumulative probability 43.6%.
- Higher growth rates when abutting/displacing the optic chiasm; no visual field impact within 6 months among enlarging tumors not contacting the chiasm.
- With continued monitoring after first enlargement (median 2.6 years): further growth 60.5%, stability 35.5%, shrinkage 4.0%.
- New anterior pituitary deficits 4.0–4.9%, mainly associated with tumor enlargement.
- Postoperative outcomes: hypopituitarism reversal 12–17%; new deficits 12–15%; permanent vasopressin deficiency 3.5%.
Methodological Strengths
- Large multicenter cohort (21 departments) with standardized capture of imaging and hormonal outcomes.
- Long follow-up window (up to 5-year cumulative probabilities) enabling time-to-event estimates.
Limitations
- Retrospective design with potential selection and information biases.
- Heterogeneity in local imaging schedules and thresholds for endocrine testing and surgery.
Future Directions: Prospective validation of risk-adapted surveillance algorithms, patient-reported outcomes, and cost-effectiveness analyses to optimize follow-up intensity.
OBJECTIVE: Surveillance is often adopted for asymptomatic non-functioning pituitary macroadenomas (macroNFPAs). Due to low-quality evidence, uncertainty remains on optimal frequency of imaging/biochemical monitoring and indications for surgery. We assessed the natural history and outcomes of patients with macroNFPA who had monitoring as initial management choice from the UK NFPA Consortium. DESIGN: This was a multicentre, retrospective, cohort study involving 21 UK endocrine departments. METHODS: Clinical, imaging, and hormonal data of 949 patients followed up between January, 1, 2005 and March, 1, 2022 were analysed. RESULTS: Incidence rate for tumour enlargement was 9.8 per 100 patient-years (95% CI, 8.8-10.8), with cumulative probabilities 1.6%, 8.1%, 18.4%, 29.2%, and 43.6% at 6-month, 1-year, 2-year, 3-year, and 5-year follow-up, respectively; rates were higher in tumours abutting/displacing optic chiasm than those not in contact with it. Amongst macroNFPAs not in contact with optic chiasm showing enlargement within 6 months, none impacted visual fields. In tumours with enlargement and continued monitoring (median 2.6 years), further growth occurred in 60.5% (33.8% probability at 2 years), stability in 35.5%, and shrinkage in 4.0%. Rates of new pituitary hormone deficits were 4.0%-4.9%, mainly driven by tumour enlargement. After transsphenoidal surgery, rates of hypopituitarism reversal were 12%-17% and those of additional anterior pituitary hormone deficits were 12%-15% (permanent vasopressin deficiency 3.5%). CONCLUSIONS: Our data provide evidence for monitoring protocols. MacroNFPAs not in contact with optic chiasm require less frequent imaging, and first follow-up scan can be delayed to 1 year. After first enlargement, variable tumour behaviour can occur. New hypopituitarism in stable tumours is rare, challenging necessity of regular pituitary function assessment.